Free Trial

Krystal Biotech Q3 2023 Earnings Report

Krystal Biotech logo
$148.39 +3.58 (+2.47%)
As of 01/17/2025 04:00 PM Eastern

Krystal Biotech EPS Results

Actual EPS
$2.79
Consensus EPS
-$1.10
Beat/Miss
Beat by +$3.89
One Year Ago EPS
-$1.17

Krystal Biotech Revenue Results

Actual Revenue
$8.60 million
Expected Revenue
$6.29 million
Beat/Miss
Beat by +$2.31 million
YoY Revenue Growth
+8,500.00%

Krystal Biotech Announcement Details

Quarter
Q3 2023
Time
Before Market Opens

Conference Call Resources

Krystal Biotech Earnings Headlines

Krystal Biotech appoints Saxena as CFO
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Positive Report for Erasca (ERAS) from Bank of America Securities
Krystal Biotech, Inc. (KRYS) Stock Forecasts
See More Krystal Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Krystal Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Krystal Biotech and other key companies, straight to your email.

About Krystal Biotech

Krystal Biotech (NASDAQ:KRYS), a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

View Krystal Biotech Profile

More Earnings Resources from MarketBeat